Precision BioSciences announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Company's CMC processes and analytical methods for azercabtagene zapreleucel (azer-cel; PBCAR0191). Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.21 USD | -0.29% |
|
+10.70% | -6.48% |
07-01 | Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell 3000E Index | CI |
07-01 | Precision BioSciences, Inc.(NasdaqCM:DTIL) added to Russell Microcap Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.48% | 70.92M | |
+27.42% | 46.56B | |
+45.38% | 41.67B | |
+0.48% | 41.16B | |
+32.66% | 32.4B | |
+20.96% | 28.18B | |
-6.35% | 28.1B | |
+48.94% | 14.52B | |
+48.30% | 13.74B | |
+2.97% | 12.17B |
- Stock Market
- Equities
- DTIL Stock
- News Precision BioSciences, Inc.
- Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate